Immune cell profiling in Gleason 9 prostate cancer patients treated with brachytherapy versus external beam radiotherapy: An exploratory study

H Wang; L C Mendez; G Morton; A Loblaw; A Mesci; H T Chung; S Chan; X Huang; M R Downes; D Vesprini; S K Liu

doi:10.1016/j.radonc.2020.10.029

Immune cell profiling in Gleason 9 prostate cancer patients treated with brachytherapy versus external beam radiotherapy: An exploratory study

Radiother Oncol. 2021 Feb:155:80-85. doi: 10.1016/j.radonc.2020.10.029. Epub 2020 Oct 24.

Authors

H Wang¹, L C Mendez², G Morton³, A Loblaw⁴, A Mesci³, H T Chung³, S Chan⁵, X Huang⁶, M R Downes⁷, D Vesprini³, S K Liu⁸

Affiliations

¹ Department of Medical Biophysics, University of Toronto, Canada; Sunnybrook Research Institute, Toronto, Canada.
² Division of Radiation Oncology, London Regional Cancer Program, London, Canada.
³ Sunnybrook Research Institute, Toronto, Canada; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada; Department of Radiation Oncology, University of Toronto, Canada.
⁴ Sunnybrook Research Institute, Toronto, Canada; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada; Department of Radiation Oncology, University of Toronto, Canada; Institute of Health Policy, Management and Evaluation, Toronto, Canada.
⁵ Sunnybrook Research Institute, Toronto, Canada; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada.
⁶ Sunnybrook Research Institute, Toronto, Canada.
⁷ Division of Anatomic Pathology, Department of Laboratory Medicine and Molecular Diagnostics, Sunnybrook Health Sciences Centre, Toronto, Canada.
⁸ Department of Medical Biophysics, University of Toronto, Canada; Sunnybrook Research Institute, Toronto, Canada; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada; Department of Radiation Oncology, University of Toronto, Canada. Electronic address: stanley.liu@sunnybrook.ca.

PMID: 33172830
DOI: 10.1016/j.radonc.2020.10.029

Abstract

This exploratory study evaluates immunological changes in high-risk Gleason 9 prostate cancer patients treated with EBRT+BT compared to EBRT alone. Notably, BT demonstrates the potential to elicit a T cell response which may support further investigation using circulating immune cells as predictive and prognostic biomarkers for radiotherapy response.

Keywords: Brachytherapy; Immune cells; Prostate cancer; Radiotherapy.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Brachytherapy*
Humans
Male
Prostatic Neoplasms* / radiotherapy
Radiotherapy Dosage
Retrospective Studies